PortfoliosLab logoPortfoliosLab logo
PBE vs. GERM
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

PBE vs. GERM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Invesco Dynamic Biotechnology & Genome ETF (PBE) and Amplify Treatments, Testing and Advancements ETF (GERM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


PBE

1D
1.99%
1M
4.32%
YTD
2.58%
6M
3.21%
1Y
32.21%
3Y*
11.28%
5Y*
3.46%
10Y*
7.59%

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

PBE vs. GERM - Yearly Performance Comparison


PBE vs. GERM - Sectors Allocation Comparison


Sectors
PBE
GERM

Healthcare

100.0%
99.3%

Financial Services

0.0%
0.4%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

PBE
100.0%
GERM
99.3%

Financial Services

PBE
0.0%
GERM
0.4%

Basic Materials

PBE

-

GERM

-

Communication Services

PBE

-

GERM

-

Consumer Cyclical

PBE

-

GERM

-

Consumer Defensive

PBE

-

GERM

-

Energy

PBE

-

GERM

-

Industrials

PBE

-

GERM

-

Real Estate

PBE

-

GERM

-

Technology

PBE

-

GERM

-

Utilities

PBE

-

GERM

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PBE vs. GERM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PBE
PBE Risk / Return Rank: 5151
Overall Rank
PBE Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
PBE Sortino Ratio Rank: 5454
Sortino Ratio Rank
PBE Omega Ratio Rank: 4848
Omega Ratio Rank
PBE Calmar Ratio Rank: 5757
Calmar Ratio Rank
PBE Martin Ratio Rank: 4747
Martin Ratio Rank

GERM
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PBE vs. GERM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PBEGERMDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.30

Calmar ratioReturn relative to maximum drawdown

2.76

Martin ratioReturn relative to average drawdown

7.74

PBE vs. GERM - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


PBEGERMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.72

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.15

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

0.33

Drawdowns

PBE vs. GERM - Drawdown Comparison

The maximum PBE drawdown since its inception was -45.69%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for PBE and GERM.


Loading charts...

Drawdown Indicators


PBEGERMDifference

Max Drawdown

Largest peak-to-trough decline

-45.69%

0.00%

-45.69%

Max Drawdown (1Y)

Largest decline over 1 year

-11.73%

0.00%

-11.73%

Max Drawdown (3Y)

Largest decline over 3 years

-22.43%

Max Drawdown (5Y)

Largest decline over 5 years

-34.71%

Max Drawdown (10Y)

Largest decline over 10 years

-37.84%

Current Drawdown

Current decline from peak

-1.71%

0.00%

-1.71%

Average Drawdown

Average peak-to-trough decline

-16.23%

0.00%

-16.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.17%

0.00%

+4.17%

Volatility

PBE vs. GERM - Volatility Comparison

Invesco Dynamic Biotechnology & Genome ETF (PBE) has a higher volatility of 5.92% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that PBE's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PBEGERMDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.92%

0.00%

+5.92%

Volatility (6M)

Calculated over the trailing 6-month period

13.42%

0.00%

+13.42%

Volatility (1Y)

Calculated over the trailing 1-year period

18.79%

0.00%

+18.79%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

22.55%

0.00%

+22.55%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

24.92%

0.00%

+24.92%

PBE vs. GERM - Expense Ratio Comparison

PBE has a 0.59% expense ratio, which is lower than GERM's 0.68% expense ratio.


Dividends

PBE vs. GERM - Dividend Comparison

PBE's dividend yield for the trailing twelve months is around 1.03%, while GERM has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PBE
Invesco Dynamic Biotechnology & Genome ETF
1.03%1.00%0.05%0.02%0.00%0.00%0.04%0.00%0.00%0.57%0.38%1.12%

Frequently Asked Questions


PBE has higher volatility (5.92%) compared to GERM (0.00%). In terms of maximum drawdown, PBE dropped -45.69% vs GERM's 0.00%.

On 1-year performance, PBE leads with 32.21% vs 0.00% for GERM. On fees, PBE is cheaper at 0.59% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, PBE has performed better with a 32.21% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

PBE is cheaper with a 0.59% expense ratio, compared with 0.68% for GERM.

PBE has the higher dividend yield at 1.03%, compared with 0.00% for GERM.

PBE tracks Dynamic Biotech & Genome Intellidex Index (AMEX), while GERM tracks Prime Treatments, Testing and Advancements Index. They also come from different issuers: Invesco and Amplify. Their fees differ too: 0.59% for PBE and 0.68% for GERM.

Portfolio Optimizer

Find the right allocation for PBE and GERM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer